Back to Search
MARK HAUGE, MD
MD
Medical Oncology Physician
NPI: 1205827466Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
23544(MN)
Research & Publications (5)
Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B).
PMID 18449005·J Thorac Oncol·2008
3-trial
Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51).
PMID 18045731·Lung Cancer·2008
3-trial
Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.
PMID 17577035·J Clin Oncol·2007
3-trial
Mutational effects on conformational changes of the dephospho- and phospho-forms of the Na+,K+-ATPase.
PMID 11331017·Biochemistry·2001
7-preclinical
Investigation of the translation-initiation factor IF2 gene, infB, as a tool to study the population structure of Streptococcus agalactiae.
PMID 10878130·Microbiology (Reading)·2000
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 601 W CHANDLER ST
ARLINGTON, MN 55307 - Phone
- (507) 964-2271
Quick Facts
- NPI
- 1205827466
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 2
- Publications
- 5
Are you this provider?
Claim Your Profile